Evaluating N-acetylcysteine efficacy in the prevention of amphotericin B-induced nephrotoxicity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107233449N8

Enrollment

Registered

2011-08-09

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal infections. Certain infectious and parasitic diseases

Interventions

Intervention 1: Intervention group: N-acetylcysteine 600 mg orally twice daily. Intervention 2: Control group: placebo 600 mg orally twice daily.

Treatment - Drugs

Intervention group: N-acetylcysteine 600 mg orally twice daily

Control group: placebo 600 mg orally twice daily

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Age between 18 to 65 years 2- Hemodynamica stability (Mean arterial pressure > 70 mmHg and Systolic blood pressure > 90 mmHg) 3- Receiving AmB for treatment of fungal infections Exclusion criteria 1- Documented history of acute kidney injury or chronic kidney disease 2- The status of kidney function at baseline is unknown 3- Receiving N-acetylcysteine (oral or parenteral) recently (during the last 1 month) 4- Documented history of hypersensitivity/anaphylactic reactions to N-acetylcysteine 5- Co-administration of antioxidants (e.g. vitamin E, vitamin C)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nephrotoxicity. Timepoint: At baseline then weekly. Method of measurement: renal function tests (BUN, Cr), serum electrolytes and biomarkers (cystatine C and KIM-1).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026